^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aspirin

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    COX inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    MATRIX-2: Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation (clinicaltrials.gov)
    P4, N=3010, Recruiting, Insel Gruppe AG, University Hospital Bern | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Sep 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    aspirin
    5d
    Thrombocytosis: Rapid Evidence Review. (PubMed, Am Fam Physician)
    The revised International Prognostic Score of Thrombosis for Essential Thrombocythemia should be calculated to stratify thrombosis risk and guide management, including when to use low-dose aspirin and cytoreductive therapy. Hydroxyurea is the first-line agent in cytoreductive therapy. No treatments have been shown to increase survival or prevent progression to myelofibrosis or leukemia in patients with essential thrombocythemia.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin) • CRP (C-reactive protein)
    |
    hydroxyurea • aspirin
    5d
    Management of advanced HR-positive breast cancer using metabolically supported chemotherapy and repurposed drugs: a case report. (PubMed, Front Oncol)
    She underwent a combinatorial protocol at ChemoThermia Oncology Center (Istanbul, Turkey) comprising of Metabolically Supported Chemotherapy (MSCT) consisting of docetaxel, doxorubicin, and cyclophosphamide administered following a 14-hour fast and low dose insulin-induced mild hypoglycemia, alongside a strict ketogenic diet (GKI < 2.0). Adjunctive therapies included local and whole-body hyperthermia, hyperbaric oxygen therapy (HBOT), and a combination of repurposed drugs (metformin, aspirin, doxycycline, mebendazole, ivermectin, and famotidine) designed to target metabolic, inflammatory, and survival pathways...A durable response in a patient with otherwise poor prognosis was achieved after systematically targeting cancer cell bioenergetics and the tumor microenvironment. These findings support further clinical investigation into multimodal metabolic therapies for advanced HR+ breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide • metformin • aspirin • mebendazole
    6d
    PEACH: Pomalidomide as an Immune-enhancing Agent for the Control of HIV (clinicaltrials.gov)
    P1/2, N=32, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    pomalidomide • aspirin
    6d
    APPART: Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology (clinicaltrials.gov)
    P3, N=1164, Recruiting, University Hospital, Toulouse | Trial completion date: May 2026 --> May 2029 | Trial primary completion date: May 2025 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    aspirin
    6d
    Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms. (PubMed, Haematologica)
    Not available.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    aspirin
    8d
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Jun 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    8d
    Administration of Aspirin and Aqueous Leaf Extract of Terminalia Catappa Reduces Leukocytosis with Risk of Developing Thrombocytosis in Diabetic Wistar Rats. (PubMed, Cardiovasc Hematol Agents Med Chem)
    Extract of Terminalia catappa, in combination with aspirin, reduced WBC count but increased platelet indices. This indicates the potential of the extract to reduce inflammation in diabetes mellitus, but with the risk of thrombocytosis.
    Preclinical • Journal
    |
    IL6 (Interleukin 6)
    |
    aspirin
    8d
    Aspirin and Preeclampsia (clinicaltrials.gov)
    P4, N=180, Recruiting, University of Chicago | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    aspirin
    9d
    Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC） (clinicaltrials.gov)
    P4, N=210, Not yet recruiting, Beijing Chao Yang Hospital
    New P4 trial
    |
    aspirin
    13d
    Older Adults' Attitudes Towards Stopping Aspirin (clinicaltrials.gov)
    P=N/A, N=2819, Completed, University of Michigan | Enrolling by invitation --> Completed | Trial completion date: Dec 2026 --> Nov 2025 | Trial primary completion date: Mar 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    aspirin
    14d
    Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    aspirin